
11/17/2026
Two University of Pittsburgh studies show protein patterns in melanoma tumors can forecast response to immunotherapy and reveal new drug targets.
PITTSBURGH — Protein patterns in melanoma tumors can predict how patients respond to immunotherapy and can be used to find promising biomarkers and drug targets, according to two University of Pittsburgh studies published Nov. 17, 2026, in the journals Cancer Discovery and Clinical Cancer Research.
Key Takeaways
-
Two studies co-led by the University of Pittsburgh investigated protein patterns in melanoma tumors to predict response to immunotherapy and identify potential therapeutic targets.
-
The Cancer Discovery study analyzed pre-treatment tumors from 183 melanoma patients across 13 molecular levels, creating a comprehensive protein atlas and identifying hundreds of potential drug targets.
-
The Clinical Cancer Research study analyzed 208 pre-immunotherapy tumor samples, identifying three protein-based tumor subtypes linked to treatment response and survival.
-
Researchers trained and independently validated a classifier model that uses protein patterns to predict immunotherapy response type and progression-free survival.
-
Researchers say with further validation the findings could become a clinical assay to guide treatment selection.
Immune checkpoint inhibitors, a type of cancer immunotherapy, have improved survival for melanoma patients over the past 15 years. Many patients do not respond, and doctors have lacked reliable ways to predict who will benefit before treatment begins.
To find answers, researchers studied the proteome—the complete set of proteins made by cells in a tissue. Protein patterns, known as predictive biomarkers, can show in advance whether a tumor is likely to respond to a given treatment.
"In 2003, we decoded the human genome. However, because proteins are the actual molecular machines that carry out the work of life, characterizing the proteomic states of tumors is critical to both understanding both the biology of tumors and identifying prognostic biomarkers," says co-senior author Diwakar Davar, M.D., associate professor at medicine at Pitt and co-leader of the Cancer Immunology and Immunotherapy Program at the UPMC Hillman Cancer Center. "Protein atlases bridge the gap between genomic possibility and therapeutic reality."
Molecular atlas of melanoma tumors maps protein patterns tied to survival
The Cancer Discovery study examined pre-treatment tumors from 183 patients with melanoma. Researchers analyzed 13 molecular levels at once, including the genome, proteome and metabolome (the full set of metabolites in a tissue).
This multi-omics approach produced a molecular atlas of the melanoma tumor microenvironment. The atlas identifies chemical alterations to proteins linked to patient survival, along with hundreds of potential targets for future drugs.
"To understand the proteomic landscape in melanoma, we needed two different sets of analyses," says Davar. "The primary tumor analysis linked changes in the genome to their protein consequences, revealing therapeutic vulnerabilities and protein patterns in untreated melanoma tumors. The characterization of melanoma tumors before combination immunotherapy revealed the tumor and immune properties that shape sensitivity or resistance to the treatment."
Three protein-based tumor subtypes predict immunotherapy response
The Clinical Cancer Research study analyzed 208 tumor samples collected before immunotherapy. The samples came from an international collaboration involving all National Cancer Institute-funded Specialized Program of Research Excellence, or SPORE, programs for melanoma.
Researchers identified three tumor subtypes based on distinct protein patterns:
-
An immune-rich group with increased immune activity
-
A proliferative group with elevated features of cell growth
-
A growth and metastasis group with characteristics tied to tumor spread
Each subtype was linked differently to treatment response. The immune-rich group responded best. Among patients who received combination immunotherapy, the subtypes also predicted disease progression and survival.
Classifier model predicts treatment response, survival across patient groups
Researchers trained a classifier model to sort tumors into one of the three groups based on protein patterns. The model was independently validated in two separate patient groups. It predicted treatment response type and progression-free survival with a high degree of certainty.
"We currently lack robust biomarkers to predict which patients will derive benefit from combination immunotherapy. A proteomic biomarker could identify tumors most likely to respond, providing the foundation for a clinical assay to guide treatment selection," said Davar. "Once translated into a validated clinical assay, the biomarker could allow pathology laboratories across the country, from Pittsburgh to Palm Beach, to help determine whether a patient is likely to benefit from treatment."
Further validation is needed before the findings can be used in clinics. Together, the two studies provide a molecular atlas and a tested classification method that could guide more personalized immunotherapy for melanoma patients.
Frequently Asked Questions
Q: What are predictive biomarkers and why do they matter for melanoma immunotherapy?
A: Predictive biomarkers are measurable features—in this case, protein patterns—that show in advance whether a tumor is likely to respond to treatment. Identifying them could help patients avoid side effects from treatments unlikely to work and start more effective options sooner.
Q: How many patients were included in the two studies?
A: The Cancer Discovery study analyzed pre-treatment tumors from 183 melanoma patients. The Clinical Cancer Research study analyzed 208 tumor samples collected before immunotherapy through an international collaboration.
Q: Is a protein-based biomarker test available to patients now?
A: Not yet. The researchers said further validation is needed before the findings could be developed into a clinical assay that pathology laboratories could use to guide treatment decisions.
Additional Resources
-
Melanoma protein patterns help predict immunotherapy response, survival | EurekAlert!
-
Immunotherapy for Melanoma | UPMC Hillman Cancer Center
Authors and Funding
Authors: Pei Wang, Ph.D., of Icahn School of Medicine, Amanda Paulovich, M.D., Ph.D., of at Fred Hutchinson Cancer Center, Marcin Cieslik, Ph.D., of University of Michigan, and Tao Liu, Ph.D., of Pacific Northwest National Laboratory are the co-senior and co-corresponding authors of current studies.
Funding and Disclosures: This research received support from the National Cancer Institute Clinical Proteomic Tumor Analysis Consortium (U24CA270823, U24CA271079, U24CA271012, U24CA271075, U24CA271076, U24CA271037, U24CA271114, U01CA271412, U01CA271410, U01CA271407, U01CA271402), National Institutes of Health (75N91019D00024, 75N91020F00030), National Cancer Institute (P30 CA015704, R50 CA211499, P50 CA225450, U54 CA263001, P50 CA121974), National Center for Advancing Translational Sciences (UL1TR004419), NIH Office of Research Infrastructure Programs (S10OD026880, S10OD030463, S10OD030225, S10OD028685), National Health and Medical Research Council of Australia (2022/GNT2018514), NIH Specialized Program of Research Excellence (SPORE) Melanoma Grant (P50 CA93459), and the Aven Foundation.